The Hedgehog signaling pathway is often aberrantly activated in various cancers, including basal cell carcinoma (BCC). By inhibiting the SMO receptor, sonidegib disrupts the Hh pathway, thereby reducing the proliferation of cancer cells and promoting cell death. This makes it an effective therapy for cancers with activated Hh signaling.
